Is serum-derived exosomal hTERT transcript a marker of oncogenic activity in primary brain tumors? An exploratory study.
Orit UzielAndrew A KannerEinat BeerySapir LevMeir LahavSuzana Horn-FichmanSagi Har NofYuseph LavivS Yust-KatzAlexandra AmielRamez Abu ShkaraMustafa SiddeeqAdva Levy-BardaPia RaananiYaron SelaZvi CohenTali SiegalPublished in: Cancer medicine (2023)
We demonstrated for the first time that the expression of e-hTERT-trans transcript can be measured in the serum of primary brain tumors. This exosomal marker carries the potential to serve as a biomarker once used in conjunction with other clinical and radiological parameters. Future studies are required to investigate whether the sensitivity could be augmented and whether it can be implemented into routine patients care.
Keyphrases
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- newly diagnosed
- poor prognosis
- rna seq
- palliative care
- prognostic factors
- peritoneal dialysis
- quality improvement
- human health
- patient reported outcomes
- climate change
- binding protein
- current status
- single cell
- long non coding rna
- case control
- health insurance